Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Target-inhibition of Galectin-3 by Inhaled TD139 in Patients with Idiopathic Pulmonary Fibrosis

Nikhil Hirani, Alison C. MacKinnon, Lisa Nicol, Paul Ford, Hans Schambye, Anders Pedersen, Ulf J. Nilsson, Hakon Leffler, Tariq Sethi, Susan Tantawi, Lise Gavelle, Robert J. Slack, Ross Mills, Utsa Karmakar, Duncan Humphries, Fredrik Zetterberg, Lucy Keeling, Lyn Paul, Philip L. Molyneaux, Feng Li, Wendy Funston, Ian A. Forrest, A. John Simpson, Michael A. Gibbons, Toby M. Maher
European Respiratory Journal 2020; DOI: 10.1183/13993003.02559-2020
Nikhil Hirani
1MRC Centre for Inflammation Research, The Queen's Medical Research Institute University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: n.hirani@ed.ac.uk
Alison C. MacKinnon
1MRC Centre for Inflammation Research, The Queen's Medical Research Institute University of Edinburgh, Edinburgh, UK
2Galecto, Inc., Copenhagen N, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alison C. MacKinnon
Lisa Nicol
1MRC Centre for Inflammation Research, The Queen's Medical Research Institute University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Ford
2Galecto, Inc., Copenhagen N, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans Schambye
2Galecto, Inc., Copenhagen N, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anders Pedersen
2Galecto, Inc., Copenhagen N, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulf J. Nilsson
3Department of Chemistry, Lund University, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hakon Leffler
4Department of Laboratory Medicine, Lund University, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tariq Sethi
2Galecto, Inc., Copenhagen N, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Tantawi
2Galecto, Inc., Copenhagen N, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lise Gavelle
2Galecto, Inc., Copenhagen N, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Slack
2Galecto, Inc., Copenhagen N, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ross Mills
1MRC Centre for Inflammation Research, The Queen's Medical Research Institute University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Utsa Karmakar
1MRC Centre for Inflammation Research, The Queen's Medical Research Institute University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duncan Humphries
1MRC Centre for Inflammation Research, The Queen's Medical Research Institute University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Duncan Humphries
Fredrik Zetterberg
2Galecto, Inc., Copenhagen N, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucy Keeling
5Exploristics, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lyn Paul
6National Institute for Health Research Respiratory Clinical Research Facility, Royal Brompton and Harefield NHS Foundation Trust, and Fibrosis Research Group, National Heart and Lung Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip L. Molyneaux
6National Institute for Health Research Respiratory Clinical Research Facility, Royal Brompton and Harefield NHS Foundation Trust, and Fibrosis Research Group, National Heart and Lung Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philip L. Molyneaux
Feng Li
1MRC Centre for Inflammation Research, The Queen's Medical Research Institute University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Funston
7Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian A. Forrest
8Respiratory Medicine Unit, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. John Simpson
7Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
8Respiratory Medicine Unit, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Gibbons
9Respiratory Department Royal Devon and Exeter NHS Foundation Trust Exeter, Institute of Biomedical and Clinical Science University of Exeter Medical School Exeter, Exeter, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toby M. Maher
6National Institute for Health Research Respiratory Clinical Research Facility, Royal Brompton and Harefield NHS Foundation Trust, and Fibrosis Research Group, National Heart and Lung Institute, Imperial College, London, UK
10Keck School of Medicine at University of Southern California, Los Angeles, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • “Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.” Nikhil Hirani, Alison C. MacKinnon, Lisa Nicol, et al. Eur Respir J 2021; 57: 2002559. - April 01, 2022

Abstract

Galectin-3 (Gal-3) is a pro-fibrotic β-galactoside-binding lectin that plays a key role in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel and potent small molecule inhibitor of Gal-3.

A randomised, double-blind, multi-centre, placebo-controlled, phase I/IIa study was conducted to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled TD139 in 36 healthy subjects and 24 patients with IPF (NCT02257177). Six dose cohorts of six healthy subjects were evaluated (4:2 TD139:placebo ratio) with single doses of TD139 (0.15 mg to 50 mg) and three dose cohorts of eight patients with IPF (5:3 TD139:placebo ratio) with once daily doses of TD139 (0.3 mg to 10 mg) for 14 days.

Inhaled TD139 was well tolerated with no significant treatment-related side effects. TD139 was rapidly absorbed, with mean Tmax values ranging from 0.6 h to 3 h and a T½ of 8 h. The concentration of TD139 in the lung was >567-fold higher than in the blood, with systemic exposure predicting exposure in the target compartment. Gal-3 expression on alveolar macrophages was reduced in the 3 mg and 10 mg dose groups compared to placebo, with a concentration-dependent inhibition demonstrated. Inhibition of Gal-3 expression in the lung was associated with reductions in plasma biomarkers centrally relevant to IPF pathobiology (PDGF-BB, PAI-1, Gal-3, CCL18 and YKL-40).

TD139 is safe and well tolerated in healthy subjects and IPF patients. It was shown to suppress Gal-3 expression on BAL macrophages and, in a concerted fashion, decrease plasma biomarkers associated with IPF progression.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Hirani reports grants from Galecto Biotech, during the conduct of the study;.

Conflict of interest: Dr. Mackinnon reports personal fees from Galecto Biotech, outside the submitted work; In addition, Dr. Mackinnon has a patent CA2,794,066 issued to Patent is fully owned by Galecto Biotech, a patent US13/832,672 issued to Patent is fully owned by Galecto Biotech, and a patent WO/2014/067986 pending to Patent is fully owned by Galecto Biotech.

Conflict of interest: Dr. Nicol reports grants from Galecto Biotech, during the conduct of the study; personal fees from Lecture fees received for delivering a presentation on the early detection of IPF to an audience of GPs. Training day was sponsored by Boehringer Ingelheim., outside the submitted work;.

Conflict of interest: Dr. Ford reports personal fees and non-financial support from Galecto, during the conduct of the study; In addition, Dr. Ford has a patent TD139 issued.

Conflict of interest: Dr. Schambye reports personal fees from Galecto Inc, outside the submitted work; In addition, Dr. Schambye has a patent WO/2016/180483 pending to Patent is fully owned by Galecto Biotech.

Conflict of interest: Dr. Pedersen reports personal fees from Galecto Biotech, outside the submitted work;.

Conflict of interest: Dr. Nilsson reports In addition, Dr. Nilsson has a patent CA2,794,066 issued to Patent is fully owned by Galecto Biotech, a patent US13/832,672 issued to Patent is fully owned by Galecto Biotech, a patent WO/2014/067986 pending to Patent is fully owned by Galecto Biotech, a patent WO/2005/113569 pending to Patent is fully owned by Galecto Biotech, a patent WO/2009/139719 pending to Patent is fully owned by Galecto Biotech, and a patent null pending.

Conflict of interest: Dr. Leffler reports In addition, Dr. Leffler has a patent CA2,794,066 issued to Patent is fully owned by Galecto Biotech, a patent US13/832,672 issued to Patent is fully owned by Galecto Biotech, a patent WO/2014/067986 pending to Patent is fully owned by Galecto Biotech, and a patent WO/2005/113569 pending to Patent is fully owned by Galecto Biotech.

Conflict of interest: Dr. Sethi reports personal fees from Galecto Biotech, outside the submitted work; In addition, Dr. Sethi has a patent CA2,794,066 issued to Patent is fully owned by Galecto Biotech, a patent US13/832,672 issued to Patent is fully owned by Galecto Biotech, and a patent WO/2014/067986 pending to Patent is fully owned by Galecto Biotech.

Conflict of interest: Dr. Tantawi reports personal fees from Galecto Biotech, outside the submitted work;.

Conflict of interest: Dr. Gravelle reports personal fees from Galecto Biotech, outside the submitted work; In addition, Dr. Gravelle has a patent WO/2017/103109 pending.

Conflict of interest: Dr. Slack reports personal fees from Galecto Biotech, outside the submitted work;.

Conflict of interest: Dr. Mills has nothing to disclose.

Conflict of interest: Dr. Karmakar has nothing to disclose.

Conflict of interest: Dr. Humphries has nothing to disclose.

Conflict of interest: Dr. Zetterberg reports personal fees from Galecto Biotech, outside the submitted work;.

Conflict of interest: Dr. Keeling has nothing to disclose.

Conflict of interest: Mrs Paul has nothing to disclose.

Conflict of interest: Dr. Molyneaux, via his institution received industry-academic funding from AstraZeneca and has received speaker and consultancy fees from Boehringer Ingelheim and Hoffman-La Roche outside the submitted work.Dr. Molyneaux reports personal fees from Boehringer Ingelheim, personal fees from Hoffman-La Roche, other from AstraZeneca, outside the submitted work;.

Conflict of interest: Dr. LI has nothing to disclose.

Conflict of interest: Dr. Funston has nothing to disclose.

Conflict of interest: Dr. Forrest reports personal fees from Boehringer Ingelheim, personal fees from Roche Ltd, outside the submitted work;.

Conflict of interest: Dr. Simpson has nothing to disclose.

Conflict of interest: Dr. Gibbons has nothing to disclose.

Conflict of interest: TMM has, via his institution, received industry-academic funding from Astra Zeneca and GlaxoSmithKline R&D and has received consultancy or speakers fees from Astra Zeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, GlaxoSmithKline R&D, Indalo, Novartis, Pliant, Respivant, Roche and Samumed.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received June 29, 2020.
  • Accepted November 5, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by/4.0/

This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.

PreviousNext
Back to top
View this article with LENS
Vol 59 Issue 5 Table of Contents
European Respiratory Journal: 59 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Target-inhibition of Galectin-3 by Inhaled TD139 in Patients with Idiopathic Pulmonary Fibrosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Target-inhibition of Galectin-3 by Inhaled TD139 in Patients with Idiopathic Pulmonary Fibrosis
Nikhil Hirani, Alison C. MacKinnon, Lisa Nicol, Paul Ford, Hans Schambye, Anders Pedersen, Ulf J. Nilsson, Hakon Leffler, Tariq Sethi, Susan Tantawi, Lise Gavelle, Robert J. Slack, Ross Mills, Utsa Karmakar, Duncan Humphries, Fredrik Zetterberg, Lucy Keeling, Lyn Paul, Philip L. Molyneaux, Feng Li, Wendy Funston, Ian A. Forrest, A. John Simpson, Michael A. Gibbons, Toby M. Maher
European Respiratory Journal Jan 2020, 2002559; DOI: 10.1183/13993003.02559-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Target-inhibition of Galectin-3 by Inhaled TD139 in Patients with Idiopathic Pulmonary Fibrosis
Nikhil Hirani, Alison C. MacKinnon, Lisa Nicol, Paul Ford, Hans Schambye, Anders Pedersen, Ulf J. Nilsson, Hakon Leffler, Tariq Sethi, Susan Tantawi, Lise Gavelle, Robert J. Slack, Ross Mills, Utsa Karmakar, Duncan Humphries, Fredrik Zetterberg, Lucy Keeling, Lyn Paul, Philip L. Molyneaux, Feng Li, Wendy Funston, Ian A. Forrest, A. John Simpson, Michael A. Gibbons, Toby M. Maher
European Respiratory Journal Jan 2020, 2002559; DOI: 10.1183/13993003.02559-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volumes and survival in chronic lung allograft dysfunction
  • Prediction of new-onset asthma and nasal allergy
  • Mortality and causes of death in HIV/tuberculosis patients
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society